Search research articles
Contact Us
Filters
Showing results (221-230 of 273) with videos related to
Page
of 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
Sai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 29, 2025
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Sabine Schmid, Georgia Dimopoulou, Paul van Schil, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.
Histopathology
|
April 26, 2020
Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade
Yu Z Zhang, Cecilia Brambilla, Philip L Molyneaux, et al.
NPJ Precision Oncology
|
March 12, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Gary Middleton, Helen L Robbins, Peter Fletcher, et al.
JCO Global Oncology
|
March 14, 2024
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India
Aju Mathew, Sissmol Davis, Jeffrey Mathew Boby, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss
Simon J Crabb, Karen Martin, Julia Abab, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
James Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
Lung Cancer (Auckland, N.Z.)
|
June 28, 2024
Top 20 <i>EGFR+</i> NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating <i>EGFR</i> Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 273) with videos related to
Sort By:
Page
of 28
Lung Cancer (Amsterdam, Netherlands)
|
November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
Sai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 29, 2025
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Sabine Schmid, Georgia Dimopoulou, Paul van Schil, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.
Histopathology
|
April 26, 2020
Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade
Yu Z Zhang, Cecilia Brambilla, Philip L Molyneaux, et al.
NPJ Precision Oncology
|
March 12, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Gary Middleton, Helen L Robbins, Peter Fletcher, et al.
JCO Global Oncology
|
March 14, 2024
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India
Aju Mathew, Sissmol Davis, Jeffrey Mathew Boby, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss
Simon J Crabb, Karen Martin, Julia Abab, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
James Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
Lung Cancer (Auckland, N.Z.)
|
June 28, 2024
Top 20 <i>EGFR+</i> NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating <i>EGFR</i> Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, et al.
Page
of 28